Tri-heart Plus label

Tri-heart Plus

Tri-heart Plus Recall

Get an alert when a recall is issued.

Side Effects & Adverse Reactions

There is currently no warning information available for this product. We apologize for any inconvenience.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

There is currently no usage information available for this product. We apologize for any inconvenience.

History

There is currently no drug history available for this drug.

Other Information

There are no additional details available for this product.

Tri-heart Plus Manufacturers

  • Intervet, Inc. A Subsidiary Of Merck And Company, Inc.
    Tri-heart Plus | Intervet, Inc. A Subsidiary Of Merck And Company, Inc.
    No Recall

    Tri-heart Plus | Intervet, Inc. A Subsidiary Of Merck And Company, Inc.

    Tri-heart Plus | Intervet, Inc. A Subsidiary Of Merck And Company, Inc.

    DOSAGE: Tri-Heart® Plus ivermectin/pyrantel chewable tablets should be administered orally at monthly intervals at the
    recommended minimum dose level of 6 mcg of ivermectin per kilogram (2.72 mcg/lb) and 5 mg of pyrantel (as
    pamoate salt) per kg (2.27 mg/Ib) of body weight. The recommended dosing schedule for prevention of canine
    heartworm disease and for the treatment and control of ascarids and hookworms is as follows:

    Dog Weight
    Chewable Tablets
    per Month Ivermectin
    Content Pyrantel
    Content Color Coding on
    Blister Card and Carton Up  to 25 lbs. 1 68 mcg 57 mg Blue 26 to 50 lbs. 1 136 mcg 114 mg Green 51 to 100 lbs. 1 272 mcg 227 mg Brown

    Tri-Heart® Plus ivermectin/pyrantel chewable tablets are recommended for dogs 6 weeks of
    age and older. For dogs over 100 lbs, use the appropriate combination of these tablets.

    ADMINISTRATION: Remove only one chewable tablet at a time from the blister card.
    Because most dogs find Tri-Heart®t Plus chewable tablets palatable, the product can be
    offered to the dog by hand. Alternatively, it may be added intact to a small amount of dry food
    or placed in the back of the dog’s mouth for forced swallowing.

    Care should be taken that the dog consumes the complete dose, and treated animals should
    be observed for a few minutes after administration to ensure that part of the dose is not lost
    or rejected. If it is suspected that any of the dose has been lost, redosing is recommended.

    Tri-Heart® Plus chewable tablets should be given at monthly intervals during the period of the
    year when mosquitoes (vectors), potentially carrying infective heartworm larvae, are active.
    The initial dose must be given within a month (30 days) after the dog’s first exposure to mosquitoes.
    The final dose must be given within a month (30 days) after the dog’s last exposure
    to mosquitoes.

    When replacing another heartworm preventive product in a heartworm disease preventive
    program, the first dose of Tri-Heart® Plus chewable tablets must be given within a month (30
    days) of the last dose of the former medication.

    If the interval between doses exceeds a month (30 days), the efficacy of ivermectin can be
    reduced. Therefore, for optimal performance, the chewable tablet must be given once a
    month on or about the same day of the month. If treatment is delayed, whether by a few days
    or many, immediate treatment with Tri-Heart® Plus chewable tablets and resumption of the
    recommended dosing regimen minimizes the opportunity for the development of adult
    heartworms.

    Monthly treatment with Tri-Heart® Plus chewable tablets also provides effective treatment
    and control of ascarids (T. canis, T. leonina) and hookworms (A. caninum, U. stenocephala,
    A. braziliense). Clients should be advised of measures to be taken to prevent reinfection with
    intestinal parasites.